• 4-Week Delivery: World’s fastest custom mouse model development.
  • TurboMice™ Tech: Proprietary high-efficiency gene-editing platform.
  • Full Capabilities: Expert conditional knockouts, knock-ins, and humanized models.
  • Validated Quality: Guaranteed high precision and model viability.
Partners' Projects

Trmt61a Point Mutation Mouse Model

Category Tags ,
Strain Name

Trmt61a Point Mutation Mouse Model (M01035)

Editing Type

Point Mutation

Gene Name

Trmt61a (tRNA methyltransferase 61A; catalytic subunit of tRNA m1A58 methyltransferase; human ortholog TRMT61A)

Gene Synonyms

Gcd14; Trm61; 6720458F09Rik

Strain Background

C57BL/6N

NCBI No.

Gene ID 328162

  • Cornelia de Lange syndrome mechanism — Human TRMT61A biallelic variants are established as a cause of autosomal recessive CdLS; this strain carries the genetic lesion into a whole-organism context where the developmental and translational consequences can be followed.
  • Tumour metabolism — m1A58 drives liver tumourigenesis through PPARδ translation → cholesterol synthesis → Hedgehog activation; loss of hepatic m1A suppresses DEN- and Myc-driven liver cancer in vivo.
  • T cell immunology — m1A modification promotes T cell expansion by raising MYC protein synthesis, a route into immuno-oncology readouts.
  • Haematopoietic stem cells — m1A safeguards fetal liver HSPCs from DNA damage by sustaining iron homeostasis, an emerging stress-response axis.
  • Quantitative m1A and translation study — A point mutation keeps the protein scaffold intact while changing catalytic output, which lets m1A58 levels and translational efficiency be titrated rather than simply removed.

This strain carries a defined missense mutation in the mouse Trmt61a gene, which encodes the catalytic subunit of the tRNA m1A58 methyltransferase. TRMT61A partners with TRMT6 in a heterotetramer and transfers a methyl group from S-adenosylmethionine to adenine 58 of tRNA, chiefly the initiator methionyl-tRNA (tRNAiMet); m1A58 stabilises tRNA structure and sustains translational fidelity. Because the mutation alters catalytic output rather than ablating the protein, the line is suited to dissecting graded m1A effects on protein synthesis, cell metabolism and fate — the kind of dose-dependent question a knockout cannot answer. Reported human variants in the same gene cause autosomal recessive Cornelia de Lange syndrome, making this a whole-animal model for that rare disease as well as for the m1A–translation axis in cancer and haematopoiesis.

  1. Point mutation, not ablation — The protein scaffold remains; only catalytic output changes. That separates “how much m1A is needed” from “is the protein present”, a distinction a constitutive knockout cannot make.
  2. A real human disease anchor — Biallelic TRMT61A variants (p.C108F, p.R160_T161del, p.Ala222Val) are published as the cause of autosomal recessive CdLS in two independent families. Very few tRNA-modification genes have a defined Mendelian disease to model; this one does.
  3. In vivo tumour evidence already exists — Hepatic Trmt61a deletion suppresses DEN- and Myc-induced liver cancer via the m1A–PPARδ–cholesterol–Hedgehog axis, giving customers a validated phenotype to reproduce or extend.
  4. Connects to immune and stem-cell biology — m1A boosts T cell expansion through MYC translation efficiency, and protects fetal liver HSPCs from DNA damage via iron homeostasis, opening two directions the m1A field is actively moving into.
  5. Low background expression means a clean genetic handle — Trmt61a is expressed broadly but at low level (adult ovary RPKM 16.2, adrenal 12.4, across 30 tissues), so a defined activity change is readable against a shallow baseline rather than buried under high endogenous signal.

FAQ

Game-changing benefits?

While competitors highlight germline efficiency gains, shorter timelines and enhanced 3Rs animal welfare benefits for their technologies, these are merely incremental improvements over traditional approaches. In sharp contrast, our proprietary technology delivers fully pure, homogeneous lineages—every single cell of the mice is derived exclusively from totipotent ES cells, with guaranteed 100% germline transmission efficiency. To experience these unparalleled benefits firsthand, enquire about your custom mouse model project with us or order embryos for in-house validation at your facility.

•Free initial design proposal with zero obligations.​
•Request a free quote!

All model generation projects of Mingceler operate under a fee-for-service framework.
IP Ownership: All intellectual property rights related to custom mouse models, including derived organs, tissues, cells, and biological materials, are the sole and exclusive property of the Client.
Third-Party Transfer Permission: The Client may independently decide to retain, utilize, or commercialize their custom models project materials (e.g., targeting vectors, ES cells, mouse lines) without the need for prior consent from Mingceler.
Licensing Exemption: The Client has full autonomy over all uses of the custom models or their derivatives, including but not limited to commercialization, distribution to third parties, and publication involving model data. No written license from Mingceler is required for such uses.

This website uses cookies

We use cookies to personalize content, provide social media features, and analyze our traffic. We also share information about your use of our site with our analytics partners. You can change your preferences at any time. For more information, please see our Privacy Policy Cookie Policy